ArticleFrontiers in pharmacology2017
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Pyrazole-thiazolidine hybrids as α-amylase inhibitor: a mechanistic and computational investigation.Die Naturwissenschaften · 2026Article
- Neuroprotective Mechanisms of Ficus deltoidea in an Alzheimer's Disease-Like Rat Model: Targeting Tau Hyperphosphorylation Through Glycogen Synthase Kinase-3 Beta and Protein Phosphatase 2A Regulation.Neurochemical research · 2026Article
- Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.Frontiers in cell and developmental biology · 2026Review
- Phyto-pharmacological wonders of genusSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Natural Flavonoid Apigenin, an Effective Agent Against Nervous System Cancers.Molecular neurobiology · 2024Review
- Recent advances in flavonoid compounds for the treatment of prostate cancer.Molecular biology reports · 2024Review
- CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.Journal of cancer research and clinical oncology · 2023Review
- Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells.Metabolites · 2023Review
- Platelet‑related parameters as potential biomarkers for the prognosis of sepsis.Experimental and therapeutic medicine · 2023Article
- Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia.Current issues in molecular biology · 2023Review
- Article
- Crude extract ofExploration of targeted anti-tumor therapy · 2023Article
- Medicinal Plants with Anti-Leukemic Effects: A Review.Molecules (Basel, Switzerland) · 2021Review
- Histopathological evaluation ofVeterinary world · 2021Article
- Isovitexin Suppresses Stemness of Lung Cancer Stem-Like Cells through Blockage of MnSOD/CaMKII/AMPK Signaling and Glycolysis Inhibition.BioMed research international · 2021Article
- Review
- Phytochemical profile and antiproliferative effect of Ficus crocata extracts on triple-negative breast cancer cells.BMC complementary medicine and therapies · 2020Article
- Brazilian Red Propolis: Extracts Production, Physicochemical Characterization, and Cytotoxicity Profile for Antitumor Activity.Biomolecules · 2020Article
- Article
- Dietary Compounds for Targeting Prostate Cancer.Nutrients · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.